Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 18
- Jan 20, 2024
Neoadjuvant botensilimab plus balstilimab (BOT/BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
Kasi, et. al.
Filter by
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Connective Tissue Oncology Society (CTOS)
Nov 18, 2022
A Phase IA/IB study of Botensilimab, a novel innate/adaptive immune activator, plus Balstilimab for the treatment of patients with sarcoma
Wilky, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 11, 2022
Botensilimab, a novel Fc-enhanced anti-CTLA-4 antibody enhances T cell: APC functionality and promotes superior anti-tumor immunity
Levey, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 12, 2022
Botensilimab, a novel innate/adaptive immune activator with balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
Wilky, et al.
AGEN2373 (CD137 Agonist), INCAGN1876 (GITR Agonist), INCAGN1949 (OX40 Agonist)
Human Antibodies
Jan 1, 2017
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities
Waight, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 29
- Jul 2, 2022
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
Bullock, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Journal of Clinical Oncology
Dec 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Future Oncology
Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Clinical Cancer Research
Jul 1, 2022
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny B, et al.
Frontiers in Immunology
Aug 7, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
AGEN1884 and AGEN2041: Two Functionally Distinct anti-CTLA-4 Antagonist Antibodies.
Drouin, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model.
Drouin, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 2
- Jun 6, 2017
Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies.
Wilky, et al.